These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21968463)

  • 41. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
    Kaira K; Sunaga N; Yanagitani N; Kawata T; Utsugi M; Shimizu K; Ebara T; Kawamura H; Nonaka T; Ishikawa H; Sakurai H; Suga T; Hara K; Hisada T; Ishizuka T; Nakano T; Mori M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):109-14. PubMed ID: 18929446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
    van Groeningen CJ; Peters GJ; Schornagel JH; Gall H; Noordhuis P; de Vries MJ; Turner SL; Swart MS; Pinedo HM; Hanauske AR; Giaccone G
    J Clin Oncol; 2000 Jul; 18(14):2772-9. PubMed ID: 10894878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.
    Kusaba H; Esaki T; Kishimoto J; Uchino K; Arita S; Kumagai H; Mitsugi K; Akashi K; Baba E
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):29-34. PubMed ID: 23228984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
    Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
    Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
    Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer.
    Holländer C; Baeksgaard L; Sorensen M; Albertsson P; Damstrup L; Lassen U
    Anticancer Res; 2012 Sep; 32(9):4019-23. PubMed ID: 22993353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I study of nedaplatin prior to S-1 in patients with locally advanced head and neck squamous cell carcinoma.
    Sato D; Kogashiwa Y; Tsukahara K; Yamauchi K; Kohno N
    Chemotherapy; 2013; 59(4):314-8. PubMed ID: 24480865
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies.
    Yip D; Karapetis C; Strickland AH; Steer C; Holford C; Knight S; Harper P
    Ann Oncol; 2003 Jun; 14(6):864-6. PubMed ID: 12796023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
    Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.
    Yoshino T; Hyodo I; Nishina T; Narahara H; Sugimoto N; Yoshisue K; Boku N
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):107-116. PubMed ID: 27933371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Phase I study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer].
    Horiguchi J; Takata D; Rokutanda N; Nagaoka R; Tokiniwa H; Odawara H; Kikuchi M; Sato A; Takeyoshi I
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1175-80. PubMed ID: 24047774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
    Stathis A; Hotte SJ; Chen EX; Hirte HW; Oza AM; Moretto P; Webster S; Laughlin A; Stayner LA; McGill S; Wang L; Zhang WJ; Espinoza-Delgado I; Holleran JL; Egorin MJ; Siu LL
    Clin Cancer Res; 2011 Mar; 17(6):1582-90. PubMed ID: 21278245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
    Kupsch P; Henning BF; Passarge K; Richly H; Wiesemann K; Hilger RA; Scheulen ME; Christensen O; Brendel E; Schwartz B; Hofstra E; Voigtmann R; Seeber S; Strumberg D
    Clin Colorectal Cancer; 2005 Sep; 5(3):188-96. PubMed ID: 16197622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
    Sakiyama T; Tsurutani J; Iwasa T; Kawakami H; Nonagase Y; Yoshida T; Tanaka K; Fujisaka Y; Kurata T; Komoike Y; Nishio K; Nakagawa K
    Br J Cancer; 2015 Mar; 112(5):819-24. PubMed ID: 25654665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxaliplatin - A Case Report].
    Morimoto T; Yata Y; Yonenaga Y; Hanaki K; Mise M; Higaside S; Kanda Y; Noda H
    Gan To Kagaku Ryoho; 2015 Jun; 42(6):743-5. PubMed ID: 26199249
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.
    Nemunaitis J; Hochster HS; Lustgarten S; Rhodes R; Ebbinghaus S; Turner CD; Dodion PF; Mita MM
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):336-42. PubMed ID: 23615181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. S-1: a promising new oral fluoropyrimidine derivative.
    Saif MW; Syrigos KN; Katirtzoglou NA
    Expert Opin Investig Drugs; 2009 Mar; 18(3):335-48. PubMed ID: 19243284
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
    Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
    J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.